Aggressive cancers in the epithelial-to-mesenchymal transition (EMT) phase are characterized by loss of cell adhesion, repression of E-cadherin and increased cell mobility. Non-small cell lung cancer (NSCLC) differs in basal level of E-cadherin; predominantly exhibiting silenced expression due to epigenetic-related modifications. Accordingly, effective treatments are needed to modulate these epigenetic events that in turn can positively regulate E-cadherin levels. Herein, we investigated silibinin, a natural flavonolignan with anti-cancer efficacy against lung cancer, either alone or in combination with epigenetic therapies to modulate E-cadherin expression in a panel of NSCLC cell lines. Silibinin combined with HDAC inhibitor Trichostatin A (TSA) or DNMT inhibitor 5′-Aza-deoxycytidine (Aza) significantly restored E-cadherin levels in NSCLC cells harboring epigenetically silenced E-cadherin expression. These combination treatments also strongly decreased the invasion/migration of these cells, which further emphasized the biological significance of E-cadherin restoration. Treatment of NSCLC cells, with basal E-cadherin levels, by silibinin further increased the E-cadherin expression and inhibited their migratory and invasive potential. Additional studies showed that silibinin alone as well as in combination with TSA or Aza down modulate the expression of Zeb1, which is a major transcriptional repressor of E-cadherin. Overall these findings demonstrate the potential of combinatorial treatments of silibinin with HDAC or DNMT inhibitor to modulate EMT events in NSCLC cell lines, leading to a significant inhibition in their migratory and invasive potentials. These results are highly significant, since loss of E-cadherin and metastatic spread of the disease via EMT is associated with poor prognosis and high mortalities in NSCLC.
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Introduction
Lung cancer is a deadly malignancy that is the leading cause of cancer-related mortalities globally (Ferlay et al., 2010) . Despite the advancements in treatment options, the 5-year survival rate for lung cancer remains ~15%. This is primarily attributed to the early metastatic spread of the disease within the lung and to distant organs, which involves epithelial-to-mesenchymal transition (EMT) of lung cancer cells including Non-small cell lung cancer (NSCLC) cells (Denlinger et al., 2010) . NSCLC cells differ widely in their basal level of E-cadherin, which is an epithelial marker and responsible for the 'integrity of the cell' by maintaining cell polarity, cell shape and cell-cell contact (Lim et al., 2000; Bremnes et al., 2002; Chaffer and Weinberg, 2011) .
The differential expression of E-cadherin in NSCLC cell lines is due to its epigenetic silencing via deacetylation-and methylation-related events regulated by epigenetic enzymes, e.g. histone deacetylases (HDACs) and DNA methyltransferases (DNMTs) which deacetylate histones and methylate DNA, respectively (Johnstone, 2002; Jones and Baylin, 2002; Belinsky, 2004; Witta et al., 2006) . This condenses the chromatin and thereby mechanistically silences the expression of several tumor suppressor genes including E-cadherin (Johnstone, 2002; Jones and Baylin, 2002; Belinsky, 2004; Witta et al., 2006) .
In NSCLC cells, E-cadherin expression is down-modulated primarily through HDACs, which can be augmented by HDAC inhibitors (Marks et al., 2000; Witta et al., 2006; Kakihana et al., 2009; Zhang et al., 2009) . HDACs act in concert with other chromatin modifying enzymes particularly DNMTs which methylate the gene promoter regions; E-cadherin has been reported to undergo methylation in ~18% of the NSCLC tumor samples, as well as in NSCLC cell lines including H1299 (Zochbauer-Muller et al., 2001; Shames et al., 2006; Tang et al., 2009 ).
Furthermore, loss of E-cadherin is an important parameter associated with resistance to EGFR This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on March 5, 2013 as DOI: 10.1124 at ASPET Journals on January 15, 2018 jpet.aspetjournals.org Downloaded from JPET# 203471 5 tyrosine kinase inhibitor (TKI) therapy. Unlike resistant cells, NSCLC cell lines that are highly sensitive to EGFR TKIs retain moderate to high levels of E-cadherin (Yauch et al., 2005; Soltermann et al., 2008; Kakihana et al., 2009 ). Moreover, loss of E-cadherin is associated with poor prognosis, and is a major contributor to the early mortalities in NSCLC patients (Lim et al., 2000; Thompson et al., 2005; Yauch et al., 2005; Witta et al., 2006; Frederick et al., 2007; Soltermann et al., 2008) . In NSCLC cell lines, E-cadherin expression is modulated through two main signaling pathways namely β -catenin and zinc finger proteins including transcriptional repressors Snail, Slug, Zeb1 and SIP1 (Zeb2) (Postigo and Dean, 1999; Ohira et al., 2003; Peinado et al., 2004; Witta et al., 2006; Kakihana et al., 2009; Schmalhofer et al., 2009 ). Cooperative interactions between these transcriptional repressors and CtBP (a co-repressor complex) promote the recruitment of epigenetic enzymes such as HDACs to negatively regulate E-cadherin expression (Peinado et al., 2004; Spaderna et al., 2008; Drake et al., 2009; Gemmill et al., 2011; Aghdassi et al., 2012) . Amongst these transcriptional repressors, elevated levels of Zeb1 mRNA have been shown to be correlated with the loss of E-cadherin expression, especially in the EFGR-TKI insensitive NSCLC cell lines (Witta et al., 2006) .
Several inhibitors of epigentic enzymes have shown potential in NSCLC control, and are in clinical trials; however, their toxicity and cancer cell resistance are the limiting factors (Fantin and Richon, 2007; Issa and Kantarjian, 2009; Schrump, 2009; Robey et al., 2011; Chang et al., 2012) . Some of these drugs include HDAC inhibitors [HDACi, e.g. Trichostatin A (TSA)] and DNMT inhibitors [DNMTi, e.g. 5′-Aza-deoxycytidine (Aza)], which are used in combination with each other or other agents to potentiate/synergize their efficacy (Belinsky et al., 2003; Zhong et al., 2007; Bots and Johnstone, 2009; Meeran et al., 2010) . Thus, the overall emphasis is to develop effective and safe treatment regimens which could modulate epigenetic events in This article has not been copyedited and formatted. The final version may differ from this version. favor of positively regulating E-cadherin levels in NSCLC cell lines (Neal and Sequist, 2012) and thereby exert their anti-cancer activity.
In this regard, silibinin, a non-toxic chemopreventive agent, has shown strong anti-cancer efficacy against NSCLC cells in culture and nude mice (Mateen et al., 2010) , together with the potential to alter enzymatic activity and protein levels of HDACs in NSCLC cells (Mateen et al., 2012) . Specifically, silibinin was found to inhibit HDAC activity and decrease HDAC 1-3 levels in NSCLC cells, leading to an overall increase in global histone acetylation states of H3 and H4 (Mateen et al., 2012) . Accordingly, here we examined the effect of silibinin, either alone or in combination with epigenetic therapies (HDAC or DNMT inhibitor), on regulating the mechanisms that are responsible for silencing E-cadherin in NSCLC cells. Furthermore, we also assessed whether such molecular alterations could be translated to the biologically relevant invasion and migration events of NSCLC cells with epigenetically silenced E-cadherin levels (H1299 and H157 cells) and those with basal E-cadherin levels (H322 and H358 cells).
Methods
Cell Culture and Treatments. NSCLC cell lines were purchased from ATCC (Manassas, VA), and were tested and authenticated by polymorphic short tandem repeat profiling. Cells were cultured in RPMI 1640 containing 10% FBS and 100 U/ml of penicillin G, and 100 mg/ml of streptomycin sulfate and maintained at 37°C in a humidified 5% CO2 incubator. Statistical Analyses: Difference between treatment groups was determined by one-way ANOVA followed by Bonferroni t test using Sigma stat 2.03 software (Jandel Scientific). Two sided, P values < 0.05, were considered significant. analyzed by immunoblotting for E-cadherin expression (Fig.1A) . Silibinin alone could not reexpress the epigenetically-silenced E-cadherin levels during 24-48 hrs of its treatment (data not shown because the immunoblot for E-cadherin was totally blank). However, exposure of cells to HDACi (TSA) caused an increase in E-cadherin protein levels in a dose-dependent manner; however, the increase was more evident by 24 hrs and tend to decrease by prolonged exposure (48 hrs) as has been reported earlier for this HDACi (Kakihana et al., 2009 ). Conversely, H1299 cells treated with DNMTi (Aza) did not show early restoration of E-cadherin expression but the drug significantly increased E-cadherin protein levels at later time points (48 hrs) (Fig.1A) .
Results
Differential Effects of
These results showed that in H1299 cells, HDAC and DNMT inhibitors do elevate E-cadherin protein expression, as would be expected, by inhibiting chromatin-modifying enzymes that cause E-cadherin silencing.
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Synergistic Effect of Silibinin in Combination with Epigenetic Therapies (HDACi or
DNMTi) on the Induction of E-cadherin Expression. Next, we used one dose of TSA (0.5 µM) and Aza (5 µM) alone or in combination with low doses of silibinin (3.75-12.5 µM) and examined their effect on re-expression of E-cadherin levels in H1299 cells by immunoblotting (Fig. 1B) and IF (Fig.1C) . The doses of HDAC and DNMT inhibitors were chosen based on their effect in moderately increasing E-cadherin protein levels. As shown in Fig. 1B , co-treatments of TSA + silibinin for 24 hrs caused a marked increase in E-cadherin protein expression as compared to single agent alone. Moreover, at 48 hrs, where E-cadherin level started to gradually decline in HDACi alone treatment, silibinin combination resulted in a strong increase in Ecadherin levels. Furthermore, a combination treatment of Aza + silibinin for 48 hrs also increased E-cadherin levels, suggesting that silibinin treatments along with epigenetic drugs were effective in inducing E-cadherin levels.
Combinatorial Treatment of Silibinin with HDACi or DNMTi Inhibits the Migration and
Invasion of NSCLC H1299 Cells. E-cadherin is considered to be a master regulator of EMT and its disruption stimulates cancer cell invasion and migration, contributing to aggressive cellular phenotype (Thiery, 2002) . To understand the biological significance of E-cadherin re-expression by silibinin in combination with HDACi or DNMTi, we next conducted migration and invasion assays in H1299 cells. Cells were exposed to single or combination treatment of drugs and after 36 hrs, equal number of live cells in each treatment group was re-plated in migration chambers in presence of drugs up till the completion of 48 hrs of treatment time. Our results show that combination treatments reduced cell migration by 58% and 69% (P<0.001, for both) in TSA + silibinin and Aza + silibinin treatment groups, respectively ( Fig. 2A and 3A) . Also, whereas TSA alone was ineffective, both silibinin and Aza alone also inhibited cell migration by 26-30%
This article has not been copyedited and formatted. The final version may differ from this version. (P<0.05) and 46% (P<0.001), respectively. Next, reversibility of these effects was tested by drug wash-out studies ( Fig.2B and 3B ), wherein after initial combination treatment of cells with drugs for 36 hrs, equal live cell numbers in each treatment group were re-plated in the trans-well invasion chambers in the absence of drugs treatment up till the completion of the next 12 hrs. As shown in Fig.2B and 3B, even in the absence of further drugs treatment, silibinin in combination with either TSA or Aza was able to significantly inhibit (by 56%, and 68%, P<0.001, respectively) the migration of H1299 cells in an irreversible fashion. Next, under similar treatment conditions, the effect of these drugs treatments on the invasive potential of H1299 cells was also evaluated. The combination treatments of TSA + silibinin and Aza + silibinin significantly reduced the invasion of H1299 cells as compared to single agents alone ( Fig.4A and   4B ).
Silibinin Enhances E-cadherin Expression and Concomitantly Reduces Zeb1 levels in
NSCLC H322 and H358 Cells. To further examine silibinin effects in NSCLC cell lines that differ vastly in their E-cadherin expression, we extended our studies in H322 and H358 cell lines which are known to possess detectable E-cadherin levels (Witta et al., 2006) . As observed by IF, silibinin treatment at low dose (12.5µM) resulted in a time-dependent (expression monitored as a function of time from 0 to 120 hrs) increase in E-cadherin levels ( Fig.5A and 5B). A concomitant decrease in nuclear levels of Zeb1 was also observed in this study, suggesting that an increase in E-cadherin levels by silibinin might be associated with a decrease in the levels of its transcriptional repressor, Zeb1, in NSCLC cell lines. 13 not exhibit an increase in E-cadherin (mRNA and protein) levels by HDACi due to its suppression by Zeb1 (Kakihana et al., 2009 ). We treated H157 cells to TSA (0.33-0.5 µM) alone or in combination with silibinin (3.75-12.5 µM) for 24 hrs (Fig.7B ), and cell lysates were then analyzed for E-cadherin and Zeb1 protein levels. As illustrated in Fig.7B , HDACi treatment did not alter the levels of both E-cadherin and Zeb1 at 0.33 µM dose in H157 cells. However, at 0.5 µM dose, it did cause a decrease in Zeb1 without affecting E-cadherin levels. More importantly, addition of low doses of silibinin synergized with the lower dose (0.33 µM) of HDACi in inducing E-cadherin expression together with a decrease in Zeb1 protein levels ( Fig.7B ) though silibinin alone had no such effect (data not shown). Together, these results suggest that whereas low doses of silibinin alone cannot re-express silenced E-cadherin in NSCLC cells, silibinin could synergize with HDACi such as TSA in up regulating E-cadherin levels possibly by a down modulation of Zeb1 which is a major transcriptional repressor of E-cadherin.
Silibinin Inhibits Cellular Migration and
Discussion
Down regulation or aberrant expression of E-cadherin is identified in several human cancers including colorectal, pancreas, lung, prostate, breast, etc., where poorly differentiated tumors contain reduced levels of E-cadherin (Beavon, 2000; Strathdee, 2002; Onder et al., 2008) .
Functional inactivation of E-cadherin occurs through varying genetic (irreversible) and epigenetic (reversible) alterations as well as transcriptional silencing of the human E-cadherin gene (CDH1) (Onder et al., 2008) . Genetic mechanisms regulating E-cadherin expression include somatic mutations and loss of heterozygosity (LOH) of the wild type allele, which promotes tumorigenesis and induces tumor cell invasiveness. However, the incidence of E-cadherin mutations is rare in cancers, and alternative epigenetic mechanisms have been shown to play a 14 preferential role in silencing its gene expression (Peinado et al., 2004; Liu et al., 2005) . The changes in epigenome result in reversible alterations in its gene expression patterns, which together with various other genetic abnormalities, contribute to the onset and progression of NSCLC (Nephew and Huang, 2003; Bowman et al., 2006) . Akin to other malignacies, in NSCLC, loss of E-cadherin expression is a critical event associated with EMT and metastasis as well as cancer cell proliferation and drug resistance to apoptosis/anoikis (Onder et al., 2008; Zavadil et al., 2008; Kakihana et al., 2009 ).
E-cadherin is one of the predominant members of cadherin family that is present within epithelial cells and localized on the basolateral membrane in the adherens junctions (Thiery, 2002; Zavadil et al., 2008; Chaffer and Weinberg, 2011) . Cadherins (including E-cadherin) are a group of cell-adhesion molecules (CAMs) and are comprised of transmembrane glycoproteins responsible for maintaining cell-cell and cell-matrix adhesion (Bremnes et al., 2002) . Under normal conditions, E-cadherin has a functional role in physiological processes such as embryonic morphogenesis and wound healing (Thiery, 2002; Liu et al., 2005) . However, loss of this epithelial marker is crucial for EMT of the epithelial-derived solid tumors that acquire a mesenchymal phenotype resulting in increased tumor invasiveness and metastasis (Thiery, 2002; Onder et al., 2008; Tsuji et al., 2009; Hanahan and Weinberg, 2011) . In NSCLC, studies have linked EMT and cancer progression to inflammation, since the production of inflammatory mediators (e.g. COX-2 and PGE2) negatively regulates E-cadherin expression (Dohadwala et al., 2006) . Apart from genetic and epigenetic events, downregulation of E-cadherin in human tumors also occurs via mechanisms like proteolytic cleavage (through MMPs), internalization/degradation of E-cadherin (through Hakai-an E3 ubiqutin ligase) (Le et al., 1999; Pece and Gutkind, 2002; Nawrocki-Raby et al., 2003) . regulate E-cadherin levels and induce EMT, promoting tumor progression, invasion, and metastasis (Spaderna et al., 2008; Drake et al., 2009; Gemmill et al., 2011) . Specifically in NSCLC, Zeb1 has been shown to suppress the expression of E-cadherin by binding with its two 5΄-CACCTG (E-box) sequences (Verschueren et al., 1999; Clarhaut et al., 2009 ). Zeb1
interaction with E-cadherin promoter has been shown to involve CtBP, a transcriptional corepressor protein that further enhances the binding of HDACs to the promoter regions of Ecadherin (Postigo and Dean, 1999) . Knockdown of Zeb1 in NSCLC H661 cells has been shown to increase E-cadherin levels (Kakihana et al., 2009 ).Clinically, E-cadherin is used as a biomarker to predict responses to EGFR-TKI therapy in NSCLC patients (Witta et al., 2006; Soltermann et al., 2008) . Taken together, the overall importance of this epithelial marker clearly suggests that studies are needed to identify the agents which could re-express epigeneticallysilenced E-cadherin levels in NSCLC.
In the present study, we focused our efforts on elucidating the effects of silibinin, a nontoxic photochemical with established anti-cancer activity against various epithelial malignancies including lung cancer (Singh et al., 2006; Tyagi et al., 2009; Mateen et al., 2010; Ramasamy et al., 2011; Tyagi et al., 2011) 
